Genomic specialist Cellectis and biotech leader VitamFero have signed a research, development and licensing partnership agreement for a new generation of attenuated vaccines.

This agreement will grant VitamFero access to Cellectis’ proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines.

Under the five-year agreement, Cellectis will supply VitamFero with pre-selected meganucleases for initial use in the development of vaccines against the parasites responsible for toxoplasmosis and neosporosis, among others.

VitamFero CEO Pascal Breton said that the agreement represents an important step, by getting access to Cellectis’ intellectual propriety and strengthening its technological potential in the modification of the genomes of apicomplex parasites.